Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens

The status quo for combating uprising antibacterial resistance is to employ synergistic combinations of antibiotics. Nevertheless, the currently available combination therapies are fast becoming untenable. Combining antibiotics with various FDA-approved non-antibiotic drugs has emerged as a novel st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Maytham, Hu, Xiaohan, Paulin, Olivia K.A., Crawford, Simon, Tony Zhou, Qi, Baker, Mark, Schneider-Futschik, Elena K., Zhu, Yan, Li, Jian, Velkov, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481501/
https://www.ncbi.nlm.nih.gov/pubmed/32952938
http://dx.doi.org/10.1016/j.csbj.2020.08.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481501/
https://www.ncbi.nlm.nih.gov/pubmed/32952938
http://dx.doi.org/10.1016/j.csbj.2020.08.008

Ejemplares similares